AllSight
Companies · ANNX · Pharmaceutical Preparations

Annexon, Inc. (ANNX)

Annexon, Inc. (ANNX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Annexon, Inc. (ANNX) stock — financials & valuation

Key numbers for Annexon, Inc. (ANNX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 40/100 — a percentile rank of Annexon, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$995.3M
EV / EBITDA-3.8×
Return on equity-108.9%
ROIC1594.0%
Debt / equity0.0×
Dividend yield0.0%

Is Annexon, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Annexon, Inc.’s own financial statements and shown as context, never as advice.

Aug 12, 2026Month 24 endpoint added
Annexon widens the ARCHER II goalposts without delaying Month 15
Aug 10, 2026
Retinal specialist joins board as longtime director exits; no operating change
Aug 6, 2026
Early FORWARD data validates rapid responses, but the sample remains tiny
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact